Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

This study is testing LILRA6 CAR-T cell therapy — where a patient's own immune cells are collected, genetically engineered to recognize and destroy leukemia cells, and then given back — for people with acute myeloid leukemia (AML) that has relapsed (come back) or is refractory (not responding to treatment). **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed AML that is refractory (did not achieve remission after two rounds of standard chemotherapy) OR has relapsed after prior treatment - Your cancer was confirmed to relapse within 12 months of remission, OR did not respond to salvage chemotherapy after a later relapse - You are in adequate physical health with functioning organs **You may NOT be eligible if...** - You have AML that responded well to and remains in remission with standard treatment - You have severe heart, liver, kidney, or lung problems - You have active uncontrolled infections or autoimmune disease - You have had prior CAR-T therapy targeting LILRA6 Talk to your doctor to see if this trial is right for you.